Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameHydrocortisone
Accession NumberDB00741  (APRD01019)
Typesmall molecule
Groupsapproved
Description

The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
11beta-hydrocortisoneNot AvailableNot Available
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dioneNot AvailableNot Available
11β-hydrocortisoneNot AvailableNot Available
17-HydroxycorticosteroneNot AvailableNot Available
CortisolNot AvailableNot Available
HidrocortisonaSpanishINN
HydrocortisonumLatinINN
Kendall's compound FNot AvailableNot Available
Reichstein's substance MNot AvailableNot Available
Salts
Name/CAS Structure Properties
Hydrocortisone Acetate
Thumb
  • InChI Key: ALEXXDVDDISNDU-JZYPGELDSA-N
  • Monoisotopic Mass: 404.219888756
  • Average Mass: 404.4966
DBSALT000369
Hydrocortisone Probutate
Thumb
  • InChI Key: FOGXJPFPZOHSQS-AYVLZSQQSA-N
  • Monoisotopic Mass: 488.277403634
  • Average Mass: 488.613
DBSALT000783
Hydrocortisone Valerate
57524-89-7
Thumb
  • InChI Key: FZCHYNWYXKICIO-FZNHGJLXSA-N
  • Monoisotopic Mass: 446.266838948
  • Average Mass: 446.5763
DBSALT000782
Brand names
NameCompany
ActicortNot Available
Aeroseb HCNot Available
Ala-ScalpNot Available
AlacortNot Available
AlgicirtisNot Available
Anusol HCNot Available
Aquanil HCNot Available
Beta-HCNot Available
CaldeCORTNot Available
CetacortNot Available
CortaidNot Available
DelacortNot Available
FicortrilNot Available
GenacortNot Available
GlycortNot Available
Komed HCNot Available
Lacticare HCNot Available
LubricortNot Available
MedicortNot Available
MeusicortNot Available
Micort-HCNot Available
MildisonNot Available
Nogenic HCNot Available
NutracortNot Available
Nystaform-HCNot Available
OtocortNot Available
PandelNot Available
PenecortNot Available
PermicortNot Available
Polcort HNot Available
Preparation H Hydrocortisone CreamNot Available
PrepcortNot Available
Prevex HCNot Available
ProctocortNot Available
ProtocortNot Available
Remederm HCNot Available
SanatisonNot Available
Scalpicin CapilarNot Available
SchericurNot Available
SigmacortNot Available
SynacortNot Available
Systral HydrocortNot Available
TexacortNot Available
TimocortNot Available
WestcortNot Available
Brand mixtures
Brand NameIngredients
ActinacAllantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur
Calmurid HCHydrocortisone + Urea
CortisporinBacitracin Zinc + Hydrocortisone + Neomycin Sulfate + Polymyxin B Sulfate
Neo-CortefHydrocortisone Acetate + Neomycin Sulfate
OphthocortChloramphenicol + Hydrocortisone Acetate + Polymyxin B (Polymyxin B Sulfate)
Otizol HCHydrocortisone (Hydrocortisone Acetate) + Lidocaine (Lidocaine Hydrochloride) + Neomycin (Neomycin Sulfate)
ProctosedylDibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone
ProctosoneDibucaine Hydrochloride + Esculin + Hydrocortisone Acetate + Neomycin Sulfate
Sopamycetin HCChloramphenicol + Hydrocortisone Acetate
Ti-U-Lac HCHydrocortisone + Urea
Vioform HCClioquinol + Hydrocortisone
Vosol HCAcetic Acid + Benzethonium Chloride + Hydrocortisone + Propylene Glycol Diacetate
Categories
CAS number50-23-7
WeightAverage: 362.4599
Monoisotopic: 362.20932407
Chemical FormulaC21H30O5
InChI KeyInChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N
InChI
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Mass Specshow(2.96 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsKetosteroids; Hydroxysteroids; Cyclohexanols; Tertiary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Enolates; Polyamines; Primary Alcohols; Aldehydes
Substituents3-keto-steroid; 11-hydroxy-steroid; 17-hydroxy-steroid; 20-keto-steroid; cyclohexanol; tertiary alcohol; cyclic alcohol; secondary alcohol; ketone; primary alcohol; enolate; polyamine; alcohol; carbonyl group; aldehyde
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
PharmacodynamicsHydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
Mechanism of actionHydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
AbsorptionTopical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Volume of distributionNot Available
Protein binding95%
Metabolism

Primarily hepatic via CYP3A4

SubstrateEnzymesProduct
Hydrocortisone
6-beta-hydrocortisolDetails
Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half life6-8 hours
ClearanceNot Available
ToxicitySide effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9918
Blood Brain Barrier + 0.9383
Caco-2 permeable - 0.5096
P-glycoprotein substrate Substrate 0.7861
P-glycoprotein inhibitor I Non-inhibitor 0.7847
P-glycoprotein inhibitor II Non-inhibitor 0.8383
Renal organic cation transporter Non-inhibitor 0.7463
CYP450 2C9 substrate Non-substrate 0.8496
CYP450 2D6 substrate Non-substrate 0.9138
CYP450 3A4 substrate Substrate 0.7407
CYP450 1A2 substrate Non-inhibitor 0.9406
CYP450 2C9 substrate Non-inhibitor 0.9072
CYP450 2D6 substrate Non-inhibitor 0.9418
CYP450 2C19 substrate Non-inhibitor 0.9253
CYP450 3A4 substrate Non-inhibitor 0.8902
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9095
Ames test Non AMES toxic 0.9132
Carcinogenicity Non-carcinogens 0.9597
Biodegradation Not ready biodegradable 0.925
Rat acute toxicity 1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.95
hERG inhibition (predictor II) Non-inhibitor 0.584
Pharmacoeconomics
Manufacturers
  • Hi tech pharmacal co inc
  • Allergan herbert div allergan inc
  • Del ray laboratories inc
  • Salix pharmaceuticals inc
  • Bayer pharmaceuticals corp
  • Monarch pharmaceuticals inc
  • Valeant pharmaceuticals international
  • Westwood squibb pharmaceuticals inc
  • C and m pharmacal inc
  • Pharmaceutical assoc inc div beach products
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Altana inc
  • Ambix laboratories div organics corp america
  • Everylife
  • E fougera div altana inc
  • G and w laboratories inc
  • Ingram pharmaceutical co
  • Ivax pharmaceuticals inc
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Stiefel laboratories inc
  • Syosset laboratories inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Topiderm inc
  • Usl pharma inc
  • Vintage pharmaceuticals inc
  • Whiteworth towne paulsen inc
  • Sanofi aventis us llc
  • Coria laboratories ltd
  • Medicis pharmaceutical corp
  • Paddock laboratories inc
  • Ani pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Healthpoint ltd
  • Allergan herbert skin care div allergan inc
  • Pharmacia and upjohn co
  • Baker norton pharmaceuticals inc
  • Solvay pharmaceuticals
  • Beta dermaceuticals inc
  • Bluline laboratories inc
  • Heran pharmaceutical inc
  • Mericon industries inc
  • Perrigo co
  • Pfizer global research development
  • Carolina medical products co
  • Dermik laboratories div aventis pharmaceuticals inc
  • Torch laboratories inc
  • X gen pharmaceuticals inc
  • Jsj pharmaceuticals llc
  • Pfizer laboratories div pfizer inc
  • Barr laboratories inc
  • Elkins sinn div ah robins co inc
  • John j ferrante
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Nexgen pharma inc
  • Panray corp sub ormont drug and chemical co inc
  • Parke davis div warner lambert co
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Stiefel a gsk co
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Merck and co inc
  • Pfipharmecs div pfizer inc
  • Schwarz pharma inc
  • Able laboratories inc
  • Hr cenci laboratories inc
  • Ferndale laboratories inc
  • Akorn inc
  • Bel mar laboratories inc
  • Colgate oral pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Triax pharmaceuticals llc
  • Yamanouchi europe bv
  • Savage laboratories inc div altana inc
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories hosp products div
  • Hospira inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • International medication systems ltd
  • Taro pharmaceuticals inc
  • Ranbaxy laboratories inc
Packagers
Dosage forms
FormRouteStrength
AerosolRectal
CreamTopical
EnemaRectal
LiquidTopical
LotionTopical
OintmentOphthalmic
OintmentTopical
Powder, for solutionIntramuscular
Powder, for solutionIntravenous
TabletOral
Prices
Unit descriptionCostUnit
Locoid Lipocream 0.1% Cream 60 gm Tube335.36USDtube
Cortifoam 90 mg Foam 15 gm Can239.99USDcan
Locoid 0.1% Solution 60ml Bottle233.15USDbottle
Locoid Lipocream 0.1% Cream 45 gm Tube200.98USDtube
Locoid 0.1% Cream 45 gm Tube183.83USDtube
Locoid 0.1% Ointment 45 gm Tube174.86USDtube
Pandel 0.1% Cream 45 gm Tube161.37USDtube
Pandel 0.1% Cream 15 gm Tube138.56USDtube
Proctocort 1% Cream 28.35 gm Tube127.51USDtube
Anusol-HC 2.5% Cream 30 gm Tube106.45USDtube
Locoid Lipocream 0.1% Cream 15 gm Tube85.41USDtube
Texacort 2.5% Solution 30ml Bottle85.41USDbottle
Cortisporin 3.5-10000-1 Solution 10ml Bottle84.33USDbottle
Proctofoam HC 1-1% Foam 10 gm Can81.9USDcan
Cortisporin 3.5-10000-1 Suspension 10ml Bottle79.55USDbottle
Locoid 0.1% Solution 20ml Bottle79.28USDbottle
Cortisporin 1% Ointment 15 gm Tube75.09USDtube
Locoid 0.1% Cream 15 gm Tube67.49USDtube
Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube64.75USDtube
Locoid 0.1% Ointment 15 gm Tube62.04USDtube
Hydrocortisone Valerate 0.2% Ointment 60 gm Tube56.74USDtube
Hydrocortisone 2.5% Lotion 59 gm Bottle55.61USDbottle
Westcort 0.2% Ointment 60 gm Tube55.0USDtube
Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube54.37USDtube
Westcort 0.2% Ointment 15 gm Tube50.99USDtube
Hydrocortisone Butyrate 0.1% Cream 45 gm Tube49.43USDtube
Hydrocortisone Valerate 0.2% Ointment 45 gm Tube48.73USDtube
Hydrocortisone 2.5% Lotion 59ml Bottle47.47USDbottle
Westcort 0.2% Ointment 45 gm Tube46.97USDtube
Hydrocortisone Valerate 0.2% Cream 60 gm Tube44.99USDtube
Hydrocortisone Valerate 0.2% Cream 45 gm Tube33.99USDtube
Ala Scalp 2% Lotion 29.6ml Bottle30.99USDbottle
Hydrocortisone Valerate 0.2% Ointment 15 gm Tube30.56USDtube
Westcort 0.2% Cream 15 gm Tube25.99USDtube
Hydrocortisone Valerate 0.2% Cream 15 gm Tube19.99USDtube
Cortisporin eye drops19.74USDml
Solu-Cortef 1 g/vial17.55USDvial
Hydrocortisone 1% Lotion 118ml Bottle15.99USDbottle
Hydrocortisone Acetate 12 25 mg Suppository Box15.01USDbox
Hydrocortisone 2.5% Ointment 28.35 gm Tube13.68USDtube
Hydrocortisone 2.5% Cream 30 gm Tube13.67USDtube
Colocort 100 mg/60ml Enema 60ml Bottle13.15USDbottle
Hydrocortisone 100 mg/60ml Enema 60ml Bottle12.6USDbottle
Hydrocortisone 0.5% Cream 28.35 gm Tube11.99USDtube
Hydrocortisone 1% Cream 15 gm Tube11.99USDtube
Hydrocortisone 1% Cream 28 gm Tube11.99USDtube
Hydrocortisone Acetate 1-1% Ointment 30 gm Tube11.99USDtube
Solu-Cortef 500 mg/vial10.47USDvial
Hydrocortisone hemisucc powder9.9USDg
Cortifoam 10% aerosol9.35USDg
Hydrocortisone Sod. Succinate 1 g/vial9.01USDvial
Solu-cortef (pf) 250 mg vial8.58USDvial
Cortisporin-tc ear susp8.3USDml
Cortisporin ear suspension7.86USDml
Solu-Cortef 250 mg/vial7.05USDvial
Cortenema (100 mg/60Ml) 100 mg/enm Enema6.96USDenema
Proctofoam-hc foam6.77USDg
Cortifoam 10 % Foam6.14USDg
Hycort (100 mg/60Ml) 100 mg/enm Enema5.79USDenema
Cortamed 2.5 % Ointment5.67USDg
Hydrocortisone Sod. Succinate 500 mg/vial5.34USDvial
Hydrocortisone powder5.19USDg
Solu-cortef (pf) 100 mg vial4.85USDvial
Solu-cortef 100 mg vial4.63USDvial
Proctocort 1% cream4.37USDg
Pandel 0.1% cream4.34USDg
Locoid 0.1% lipocream4.3USDg
Solu-Cortef 100 mg/vial4.07USDvial
Locoid 0.1% cream3.92USDg
Hydrocortisone Sod. Succinate 250 mg/vial3.56USDvial
Hydrocortisone ss 250 mg vial3.5USDvial
Anusol-hc 2.5% cream3.45USDg
Hydrocortisone acet powder3.15USDg
Proctofoam2.89USDg
A-hydrocort 100 mg vial2.42USDeach
Proctocream-hc 2.5% cream2.17USDg
Hydrocortisone Sod. Succinate 100 mg/vial2.1USDvial
Hydrocortisone val 0.2% cream2.07USDg
Hytone 2.5% cream1.46USDg
Hydrocortisone buty 0.1% cream1.31USDg
First hydrocort 10% gel1.18USDg
Westcort 0.2% cream1.17USDg
Procto-kit 1% cream1.08USDg
Ala-scalp hp 2% lotion1.03USDml
Cortef 20 mg tablet0.9USDtablet
Proctosol-hc 2.5% cream0.89USDg
Proctozone-hc 2.5% cream0.83USDg
Orabase plain paste0.77USDg
Hydrocortisone 2.5% lotion0.6USDml
Cortef 10 mg tablet0.55USDtablet
Orabase-b 20% gel0.55USDg
Hydrocortisone 2.5% cream0.53USDg
Hydrocortisone 10 mg tablet0.52USDtablet
Cortef 5 mg tablet0.45USDtablet
Ala-cort 1% cream0.43USDg
Hydrocortisone 5 mg tablet0.38USDtablet
Corticaine 0.5% cream0.37USDg
Hydrocortisone 20 mg tablet0.32USDtablet
Prevex Hc 1 % Occlusive Cream0.3USDg
Emo-Cort 2.5 % Cream0.26USDg
Preparation h 1% cream0.24USDg
Tucks hydrocortisone ointment0.24USDg
Emo-Cort 2.5 % Lotion0.23USDg
Emo-Cort Scalp 2.5 % Lotion0.22USDg
Colocort 100 mg enema0.21USDml
Cortenema 100 mg enema0.21USDml
Sarna Hc 2.5 % Lotion0.2USDg
Emo-Cort 1 % Cream0.19USDg
Balneol lotion0.18USDml
Emo-Cort 1 % Lotion0.18USDg
Lanacort 1% cool creme0.18USDg
Hyderm 0.5 % Cream0.18USDg
Hytone 1% cream0.17USDg
Cortoderm Mild 0.5 % Ointment0.15USDg
Beta hc 1% lotion0.14USDml
Cortizone-10 1% spray0.14USDml
Hydroval 0.2 % Cream0.13USDg
Hydroval 0.2 % Ointment0.13USDg
Aquanil hc 1% lotion0.12USDml
Hydrocortisone plus 12 1% crm0.12USDg
Scalpicin 3% liquid0.12USDml
Slender cortisol capsule0.12USDcapsule
Cortaid 1% spray0.1USDml
Sarna Hc 1 % Lotion0.1USDg
Hydrocortisone 0.5% cream0.08USDg
Hydrocortisone 1% cream0.08USDg
Uniderm moisturizer0.05USDml
Cortoderm Regular 1 % Ointment0.04USDg
Hyderm 1 % Cream0.04USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States73784052006-12-192026-12-19
United States56354971994-06-032014-06-03
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point220 °CPhysProp
water solubility320 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.61HANSCH,C ET AL. (1995)
logS-2.97ADME Research, USCD
Caco2 permeability-4.66ADME Research, USCD
Predicted Properties
PropertyValueSource
water solubility1.99e-01 g/lALOGPS
logP1.79ALOGPS
logP1.28ChemAxon
logS-3.3ALOGPS
pKa (strongest acidic)12.58ChemAxon
pKa (strongest basic)-2.8ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count5ChemAxon
hydrogen donor count3ChemAxon
polar surface area94.83ChemAxon
rotatable bond count2ChemAxon
refractivity97.4ChemAxon
polarizability39.55ChemAxon
number of rings4ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
Spectra
References
Synthesis Reference

Manfred Baumgarth, Dieter Orth, Jurgen Harting, Hans Schaefer, Achim Zesch, “Hydrocortisone orthoesters, pharmaceutical formulations thereof and processes for the preparation thereof.” U.S. Patent US4264584, issued March, 1974.

US4264584
General Reference
  1. de Weerth C, Zijl RH, Buitelaar JK: Development of cortisol circadian rhythm in infancy. Early Hum Dev. 2003 Aug;73(1-2):39-52. Pubmed
  2. Palacios R, Sugawara I: Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor. Scand J Immunol. 1982 Jan;15(1):25-31. Pubmed
  3. KNIGHT RP Jr, KORNFELD DS, GLASER GH, BONDY PK: Effects of intravenous hydrocortisone on electrolytes of serum and urine in man. J Clin Endocrinol Metab. 1955 Feb;15(2):176-81. Pubmed
External Links
ResourceLink
KEGG DrugD00088
KEGG CompoundC00735
PubChem Compound5754
PubChem Substance46505089
ChemSpider5551
BindingDB22476
ChEBI17650
ChEMBLCHEMBL389621
Therapeutic Targets DatabaseDAP000718
PharmGKBPA449905
IUPHAR2868
Guide to Pharmacology2868
HETPDN
Drug Product Database2242930
RxListhttp://www.rxlist.com/cgi/generic/hydrocortisone.htm
Drugs.comhttp://www.drugs.com/cdi/hydrocortisone.html
PDRhealthhttp://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/hyd1199.shtml
WikipediaHydrocortisone
ATC CodesA01AC03A07EA02C05AA01D07AA02D07AB02D07AB11D07AC16D07XA01H02AB09S01BA02S01CB03S02BA01
AHFS Codes
  • 52:08.08
  • 84:06.00
  • 68:04.00
PDB EntriesNot Available
FDA labelshow(30 KB)
MSDSshow(73.6 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe corticosteroid, hydrocortisone, alters the anticoagulant effect, acenocoumarol.
Acetylsalicylic acidThe corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.
AmbenoniumThe corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, ambenonium.
AmobarbitalThe barbiturate, amobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
AnisindioneThe corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione.
AprobarbitalThe barbiturate, aprobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
Bismuth SubsalicylateThe corticosteroid, hydrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate.
ButabarbitalThe barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone.
ButalbitalThe barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone.
ButethalThe barbiturate, butethal, may decrease the effect of the corticosteroid, hydrocortisone.
CholestyramineCholestyramine may decrease the effect of hydrocortisone.
ColestipolCholestyramine decreases the effect of hydrocortisone
DicoumarolThe corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol.
Dihydroquinidine barbiturateThe barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
EdrophoniumThe corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium.
EthotoinThe enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone.
FosphenytoinThe enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
HeptabarbitalThe barbiturate, heptabarbital, may decrease the effect of the corticosteroid, hydrocortisone.
HexobarbitalThe barbiturate, hexobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
IndacaterolConcomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
Linagliptin CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
Magnesium salicylateThe corticosteroid, hydrocortisone, may decrease the effect of magnesium salicylate.
MephenytoinThe enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
MethohexitalThe barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone.
MethylphenobarbitalThe barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
MidodrineIncreased arterial pressure
NeostigmineThe corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine.
PentobarbitalThe barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
PhenobarbitalThe barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
PhenytoinThe enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone.
PrimidoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone.
PyridostigmineThe corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine.
Quinidine barbiturateThe barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone.
RifampicinThe enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone.
Salicylate-sodiumThe corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salicylate-sodium.
SalsalateThe corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate.
SecobarbitalThe barbiturate, secobarbital, may decrease the effect of the corticosteroid, hydrocortisone.
TacrineTacrine and Hydrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
TalbutalThe barbiturate, talbutal, may decrease the effect of the corticosteroid, hydrocortisone.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Trisalicylate-cholineThe corticosteroid, hydrocortisone, may decrease the effect of the salicylate, trisalicylate-choline.
VecuroniumVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
WarfarinThe corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin.
Food Interactions
  • Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.

1. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. Pubmed
  2. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. Pubmed
  3. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. Pubmed
  4. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. Pubmed
  5. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. Pubmed

2. Annexin A1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Annexin A1 P04083 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Sato-Matsumura KC, Matsumura T, Nakamura H, Sawa H, Nagashima K, Koizumi H: Membrane expression of annexin I is enhanced by calcium and TPA in cultured human keratinocytes. Arch Dermatol Res. 2000 Oct;292(10):496-9. Pubmed
  4. White MV, Igarashi Y, Lundgren JD, Shelhamer J, Kaliner M: Hydrocortisone inhibits rat basophilic leukemia cell mediator release induced by neutrophil-derived histamine releasing activity as well as by anti-IgE. J Immunol. 1991 Jul 15;147(2):667-73. Pubmed
  5. Serres M, Viac J, Comera C, Schmitt D: Expression of annexin I in freshly isolated human epidermal cells and in cultured keratinocytes. Arch Dermatol Res. 1994;286(5):268-72. Pubmed

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. Pubmed

2. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

3. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

4. Cytochrome P450 11B1, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 11B1, mitochondrial P15538 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 11B2, mitochondrial

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 11B2, mitochondrial P19099 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

1. Sex hormone-binding globulin

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Sex hormone-binding globulin P04278 Details

References:

  1. Khoromi S, Muniyappa R, Nackers L, Gray N, Baldwin H, Wong KA, Matheny LA, Moquin B, Rainer A, Hill S, Remaley A, Johnson LL, Max MB, Blackman MR: Effects of chronic osteoarthritis pain on neuroendocrine function in men. J Clin Endocrinol Metab. 2006 Nov;91(11):4313-8. Epub 2006 Aug 15. Pubmed
  2. Stroud LR, Solomon C, Shenassa E, Papandonatos G, Niaura R, Lipsitt LP, Lewinn K, Buka SL: Long-term stability of maternal prenatal steroid hormones from the National Collaborative Perinatal Project: still valid after all these years. Psychoneuroendocrinology. 2007 Feb;32(2):140-50. Epub 2007 Jan 31. Pubmed
  3. Lombardi G, Mondaini N, Macchiarella A, Del Popolo G: Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl. 2007 Sep-Oct;28(5):722-6. Epub 2007 May 9. Pubmed
  4. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA: A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007 May 15;. Pubmed
  5. Rizzo L, Dobrovsky V, Danilowicz K, Kral M, Cross G, Serra HA, Bruno OD: Low-dose glucocorticoids in hyperandrogenism. Medicina (B Aires). 2007;67(3):247-52. Pubmed

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. Pubmed
  2. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. Pubmed
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. Pubmed
  4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. Pubmed
  5. Orlowski S, Mir LM, Belehradek J Jr, Garrigos M: Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J. 1996 Jul 15;317 ( Pt 2):515-22. Pubmed

2. ATP-binding cassette sub-family G member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
ATP-binding cassette sub-family G member 2 Q9UNQ0 Details

References:

  1. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. Pubmed

3. Solute carrier organic anion transporter family member 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1A2 P46721 Details

References:

  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. Pubmed
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11